# Molecular Subtype of Small Cell Lung Cancer: Challenge for Transforming into Clinical Practice

## TL;DR

This paper discusses the challenges of translating molecular subtypes of small cell lung cancer into clinical practice.

## Contribution

The paper highlights recent advances in SCLC molecular subtyping and barriers to clinical application.

## Key findings

- SCLC was traditionally considered a homogeneous disease but is now recognized as heterogeneous.
- Molecular subtypes based on lineage transcription factors have been proposed.
- Clinical implementation of these subtypes faces significant challenges.

## Abstract

小细胞肺癌（small cell lung cancer, SCLC）是肺癌的组织学亚型之一，特点是高增殖、早转移、易耐药和复发。数年来SCLC一直被视为一种同质性疾病，治疗采用统一的放化疗策略。尽管早期疗效显著，但耐药和复发很快出现，缺乏满意的治疗效果，这可能是因为目前对SCLC的肿瘤异质性认识不足所导致。最近，临床前研究提出了基于谱系转录因子相对高表达定义的SCLC分子分型概念。本文主要阐述SCLC分子分型的现状和相关最新发现，强调分子分型转化在临床实践中所遇到的问题，旨在增进对SCLC分子分型研究进展的认识。